WO2002083727A3 - Nucleic acid sequences of hyperplasies and tumors of the thyroid - Google Patents

Nucleic acid sequences of hyperplasies and tumors of the thyroid Download PDF

Info

Publication number
WO2002083727A3
WO2002083727A3 PCT/EP2002/004090 EP0204090W WO02083727A3 WO 2002083727 A3 WO2002083727 A3 WO 2002083727A3 EP 0204090 W EP0204090 W EP 0204090W WO 02083727 A3 WO02083727 A3 WO 02083727A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
hyperplasies
tumors
thyroid
acid sequences
Prior art date
Application number
PCT/EP2002/004090
Other languages
German (de)
French (fr)
Other versions
WO2002083727A2 (en
Inventor
Joern Bullerdiek
Original Assignee
Joern Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joern Bullerdiek filed Critical Joern Bullerdiek
Priority to AU2002310840A priority Critical patent/AU2002310840A1/en
Priority to JP2002581482A priority patent/JP2005503123A/en
Priority to EP02735249A priority patent/EP1377607A2/en
Publication of WO2002083727A2 publication Critical patent/WO2002083727A2/en
Publication of WO2002083727A3 publication Critical patent/WO2002083727A3/en
Priority to US10/684,042 priority patent/US20050095594A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a nucleic acid that has a modified expression caused by hyperplasies and/or tumors, said nucleic acid comprising a nucleic acid sequence selected from the group including SEQ.ID.No. 1 to 12 and SEQ.ID.No. 16 to 19.
PCT/EP2002/004090 2001-04-12 2002-04-12 Nucleic acid sequences of hyperplasies and tumors of the thyroid WO2002083727A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002310840A AU2002310840A1 (en) 2001-04-12 2002-04-12 Nucleic acid sequences of hyperplasies and tumors of the thyroid
JP2002581482A JP2005503123A (en) 2001-04-12 2002-04-12 Thyroid hyperplasia and tumor nucleic acid sequence
EP02735249A EP1377607A2 (en) 2001-04-12 2002-04-12 Nucleic acid sequences of hyperplasies and tumors of the thyroid
US10/684,042 US20050095594A1 (en) 2001-04-12 2003-10-10 Nucleic acid sequences of hyperplasies and tumors of the thyroid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10118452.2 2001-04-12
DE10118452A DE10118452A1 (en) 2001-04-12 2001-04-12 Nucleic acid sequences from hyperplasias and thyroid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/684,042 Continuation US20050095594A1 (en) 2001-04-12 2003-10-10 Nucleic acid sequences of hyperplasies and tumors of the thyroid

Publications (2)

Publication Number Publication Date
WO2002083727A2 WO2002083727A2 (en) 2002-10-24
WO2002083727A3 true WO2002083727A3 (en) 2003-04-17

Family

ID=7681480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004090 WO2002083727A2 (en) 2001-04-12 2002-04-12 Nucleic acid sequences of hyperplasies and tumors of the thyroid

Country Status (5)

Country Link
EP (1) EP1377607A2 (en)
JP (1) JP2005503123A (en)
AU (1) AU2002310840A1 (en)
DE (1) DE10118452A1 (en)
WO (1) WO2002083727A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005011003B9 (en) * 2004-03-03 2009-02-26 Universität Leipzig Method and means for the differential diagnosis of thyroid tumors
WO2006117217A2 (en) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Novel use of spiegelmers
WO2011023413A1 (en) 2009-08-31 2011-03-03 Alcedo Biotech Gmbh Microrna-based methods and compositions for reprogramming cells
US10404099B1 (en) 2018-02-28 2019-09-03 Corning Optical Communications LLC Intermediate power supply unit for distributing lower voltage power to remote power distribution systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033982A2 (en) * 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033982A2 (en) * 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANTONINI P ET AL: "CYTOGENETIC ABNORMALITIES IN THYROID ADENOMAS", CANCER GENETICS AND CYTOGENETICS, vol. 52, no. 2, 1991, pages 157 - 164, XP002204612, ISSN: 0165-4608 *
BELGE G ET AL: "Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations.", CYTOGENETICS AND CELL GENETICS, vol. 93, no. 1-2, 2001, pages 48 - 51, XP002204613, ISSN: 0301-0171 *
BELGE G ET AL: "FISH analyses of a newly established thyroid tumor cell line showing a t(1;19)(p35 or p36:1;q13) reveal that the breakpoint lies between 19q13.3-13.4 and 19q13.4.", CYTOGENETICS AND CELL GENETICS, vol. 69, no. 3-4, 1995, pages 220 - 222, XP002204605, ISSN: 0301-0171 *
BELGE G. ET AL.: "Zytogenetische Veränderungen bei benignen Schilddrüsenhyperplasien und Adenomen korrelieren mit der Histologie", VERH. DTSCH. GES. PATH., vol. 81, 1997, pages 151 - 156, XP002204607 *
BELGE GAZANFER ET AL: "Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region.", GENES CHROMOSOMES & CANCER, vol. 20, no. 2, 1997, pages 201 - 203, XP002204604, ISSN: 1045-2257 *
BELGE GAZANFER ET AL: "Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology.", CANCER GENETICS AND CYTOGENETICS, vol. 101, no. 1, February 1998 (1998-02-01), pages 42 - 48, XP002204606, ISSN: 0165-4608 *
BICHER ANNETTE ET AL: "Loss of heterozygosity in human ovarian cancer on chromosome 19q.", GYNECOLOGIC ONCOLOGY, vol. 66, no. 1, 1997, pages 36 - 40, XP002204610, ISSN: 0090-8258 *
CLOSS ELLEN I ET AL: "Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: Three related carriers with distinct transport properties.", BIOCHEMISTRY, vol. 36, no. 21, 1997, pages 6462 - 6468, XP002204608, ISSN: 0006-2960 *
GEORGE M YOUSEF ET AL: "Prostase/KLK-L1 is a new member of the human Kallikrein gene family, is espressed in prostate and breast tissues, and is hormonally regulated", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 17, 1 September 1999 (1999-09-01), pages 4252 - 4256, XP002141958, ISSN: 0008-5472 *
GUPTA RAJNISH K ET AL: "The t(14:18) chromosomal translocation and Bcl-2 protein expression in Hodgkin's disease.", LEUKEMIA (BASINGSTOKE), vol. 8, no. 8, 1994, pages 1337 - 1341, XP002204611, ISSN: 0887-6924 *
HOSOKAWA HIROSHI ET AL: "Cloning and characterization of a brain-specific cationic amino acid transporter", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 13, 1997, pages 8717 - 8722, XP002193512, ISSN: 0021-9258 *
WANSCHURA SYLKE ET AL: "Mapping of the translocation breakpoints of primary pleomorphic adenomas and lipomas within a common region of chromosome 12.", CANCER GENETICS AND CYTOGENETICS, vol. 86, no. 1, 1996, pages 39 - 45, XP002204609, ISSN: 0165-4608 *

Also Published As

Publication number Publication date
JP2005503123A (en) 2005-02-03
DE10118452A1 (en) 2002-10-31
AU2002310840A1 (en) 2002-10-28
EP1377607A2 (en) 2004-01-07
WO2002083727A2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
WO1999057325A3 (en) Enzymes mixture
WO2001075067A8 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
JP2001515920A5 (en)
WO2002028891A3 (en) Listeria inocua, genome and applications
WO2002018424A3 (en) Nucleic acids and polypeptides
EP1209228A3 (en) Environmental stress responsive promoter
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2002083727A3 (en) Nucleic acid sequences of hyperplasies and tumors of the thyroid
WO2003035878A3 (en) Lipase variants
EP1167523A3 (en) Insertion sequence elements derived from ralstonia solanacearum
AU2001295456A1 (en) Nucleotide sequences which code for the gora gene
WO2001048185A3 (en) Transcription regulatory sequences derived from chlamydomonas reinhardtii
AU2001287631A1 (en) Nucleotide sequences which code for the metf gene
AU2001278509A1 (en) Nucleotide sequences which code for the atr43 gene
AU2001291658A1 (en) Nucleotide sequences which code for the ccpa2 gene
AU2001293808A1 (en) Nucleotide sequences which code for the atr61 gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002735249

Country of ref document: EP

Ref document number: 10684042

Country of ref document: US

Ref document number: 2002581482

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002735249

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642